Scarica l'app Stockscreener
54.92
0.77%
0.42
Dopo l'orario di chiusura:
55.00
0.08
+0.15%
Precedente Chiudi:
$54.50
Aprire:
$54.84
Volume 24 ore:
2.80M
Relative Volume:
0.98
Capitalizzazione di mercato:
$3.01B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-14.01
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
+1.12%
1M Prestazione:
+216.00%
6M Prestazione:
+463.28%
1 anno Prestazione:
+1,104%
Intervallo 1D:
$54.50
$57.57
Intervallo di 1 settimana:
$53.02
$60.70
Portata 52W:
$4.82
$60.70
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
54.92 | 3.36B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Will uniQure N.V. bounce back from current supportEarnings Beat & Safe Entry Zone Identification - newser.com
Will uniQure N.V. (UQ1) stock beat value stocksJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
uniQure N.V. stock retracement – recovery analysisDay Trade & Weekly Return Optimization Plans - newser.com
Measuring uniQure N.V.’s beta against major indices2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat
Morgan Lewis Advises UniQure in $345 Million Public Equity Offering - Morgan Lewis
Is uniQure N.V. (UQ1) stock nearing a technical breakoutWeekly Investment Report & AI Based Buy and Sell Signals - newser.com
Visual trend scoring systems applied to uniQure N.V.Quarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
How to build a custom watchlist for uniQure N.V.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Is uniQure N.V. showing signs of accumulationCEO Change & Short-Term High Return Ideas - newser.com
Is uniQure N.V. meeting your algorithmic filter criteriaJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
Wells Fargo Maintains uniQure N.V. (QURE) Overweight Recommendation - Nasdaq
Wells Fargo Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $80 - 富途牛牛
uniQure (QURE) Sees Raised Price Target and Maintained Overweigh - GuruFocus
uniQure Stock Price Target Raised on Blockbuster Opportunity - AskTraders.com
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
United States Viral Vector Manufacturing Market Set for Strong - openPR.com
uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17 - Nasdaq
uniQure NV Hits New 52-Week High of $55.11, Surging 909.48% - Markets Mojo
uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Yahoo
uniQure announces pricing of upsized $300M public offering - MSN
uniQure (NASDAQ:QURE) Reaches New 52-Week HighStill a Buy? - MarketBeat
Is uniQure N.V. stock in correction or buying zoneWeekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment - Insider Monkey
uniQure (NASDAQ:QURE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
uniQure completes $345 million public offering to fund gene therapy pipeline - Investing.com India
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - MarketScreener
Silicon Valley - FinancialContent
What drives uniQure NV stock priceStock Price Targets & Minimize Portfolio Damage with Warnings - earlytimes.in
Research Analysts Set Expectations for uniQure Q3 Earnings - MarketBeat
uniQure FY2025 EPS Forecast Reduced by Cantor Fitzgerald - MarketBeat
StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data - Genetic Engineering and Biotechnology News
uniQure (QURE) Is Up 291.6% After AMT-130’s Breakthrough Phase I/II Huntington’s Results and FDA Designations – Has The Bull Case Changed? - simplywall.st
uniQure announces $200 million proposed public offering - MSN
Why uniQure (QURE) Is Up After Positive AMT-130 Trial Results and Major New Funding Announcements - Yahoo Finance
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide - Benzinga
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook - ts2.tech
uniQure N.V.: CFO Klemt sells $945k in shares By Investing.com - Investing.com Canada
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 3,000 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Sells $825,000.00 in Stock - MarketBeat
uniQure NV Hits New 52-Week High of $54.98, Up 878.62% - Markets Mojo
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.68%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):